Search

Royalty Pharma PLC (Class A)

Ouvert

SecteurSoins de santé

58.1 -0.27

Résumé

Variation du prix de l'action

24h

Actuel

Min

57.65

Max

58.48

Chiffres clés

By Trading Economics

Revenu

-589M

-295M

Ventes

44M

674M

P/E

Moyenne du Secteur

31.419

55.725

BPA

1.32

Rendement du dividende

1.56

Marge bénéficiaire

-43.713

Employés

100

EBITDA

-387M

176M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+12.74% upside

Dividendes

By Acuity

Rendement du dividende

Moyenne du Secteur

1.56%

2.25%

Prochains Résultats

4 nov. 2026

Date du Prochain Dividende

9 déc. 2026

Date du Prochain Détachement de Dividende

13 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

848M

34B

Ouverture précédente

58.37

Clôture précédente

58.1

Sentiment de l'Actualité

By Acuity

15%

85%

11 / 339 Classement par Healthcare

Royalty Pharma PLC (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 sept. 2026, 19:25 UTC

Royalty Pharma PLC shares are rising, reflecting notable market strength, although they remain below the 20-day moving average and near the one-month range's lower end.

23 sept. 2026, 19:51 UTC

Royalty Pharma PLC shares fell sharply, reaching a session low just before 1 PM, as the broader market declines and remains below its 20-day moving average.

22 sept. 2026, 20:06 UTC

Correlated Moves

Royalty Pharma PLC is trading higher, likely influenced by Amgen Inc.'s positive Phase 3 OASIZ 301 study results, despite earlier pulling back from a session high.

21 sept. 2026, 20:06 UTC

Royalty Pharma PLC's shares are trading roughly flat, remaining below the 20-day moving average and near the lower end of their one-month range.

18 sept. 2026, 20:06 UTC

Royalty Pharma PLC shares fell sharply on Friday, closing significantly below its 20-day moving average and near the lower end of its one-month range.

17 sept. 2026, 23:06 UTC

Royalty Pharma PLC declined in after-market trading, moving lower since Thursday's close and positioning it below its 20-day moving average.

16 sept. 2026, 23:06 UTC

Royalty Pharma PLC is trading lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

15 sept. 2026, 23:16 UTC

News

Royalty Pharma announced a $7.5 million donation to Blood Cancer United. Shares are lower in after-market trading amid rising Treasury yields.

14 sept. 2026, 20:07 UTC

Royalty Pharma PLC shares are higher today, reflecting a modest gain since Friday. Broader market concerns over rising crude oil prices may be influencing sentiment.

11 sept. 2026, 20:08 UTC

Royalty Pharma PLC shares are lower today, pulling back from earlier gains amid broader market dynamics and inflation pressures influencing Federal Reserve policy.

10 sept. 2026, 23:46 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing a rise since Thursday's close, though still below the 20-day moving average.

9 sept. 2026, 20:07 UTC

News

Royalty Pharma shares lower today, following a decline after Novartis' trial failure. Analysts suggest the drop may be overdone amid stable royalty expectations.

8 sept. 2026, 21:01 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting broader market dynamics despite no specific company news identified.

5 sept. 2026, 00:01 UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

4 sept. 2026, 22:14 UTC

Royalty Pharma PLC shares are trading lower during after-market hours, breaking a trend of higher daily closes. No specific news was identified for the decline.

3 sept. 2026, 23:05 UTC

Royalty Pharma PLC shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2 sept. 2026, 23:06 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting a slight decline since Wednesday's close, despite earlier recovery attempts.

1 sept. 2026, 20:09 UTC

Royalty Pharma PLC is rising as strength in the pharmaceuticals sub-sector boosts shares. The stock remains near its one-month high despite a recent pullback.

31 août 2026, 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting positive market sentiment. The stock remains near the upper end of its one-month trading range.

28 août 2026, 20:07 UTC

Royalty Pharma PLC shares are lower today amid broader market declines and rising U.S. Treasury yields, reflecting ongoing volatility in the pharmaceuticals sector.

27 août 2026, 23:11 UTC

Royalty Pharma PLC shares are higher in after-market trading, supported by a favorable performance backdrop and positioning above the 20-day moving average.

26 août 2026, 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, currently above their 20-day moving average and near the upper end of their one-month range.

25 août 2026, 20:07 UTC

Royalty Pharma PLC shares are higher today, continuing an upward trend since Monday. Lower Treasury yields are supporting investor sentiment in the market.

24 août 2026, 20:06 UTC

Royalty Pharma PLC shares are near unchanged as market sentiment is influenced by rising oil prices and geopolitical tensions from new U.S. sanctions against Iran.

21 août 2026, 19:26 UTC

Royalty Pharma PLC shares are higher, reflecting a broader rebound in U.S. stocks amid economic uncertainties and rising inflation. The asset remains above its 20-day moving average.

20 août 2026, 23:11 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline from earlier in the session amid mixed broader market sentiment.

19 août 2026, 20:02 UTC

Royalty Pharma PLC shares are higher today, driven by strong investor interest in pharmaceuticals and unusually high market volume during regular trading hours.

18 août 2026, 23:21 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing an upward trend from previous sessions. No specific news was identified for this movement.

17 août 2026, 19:36 UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

15 août 2026, 00:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

Comparaison

Variation de prix

Royalty Pharma PLC (Class A) prévision

Objectif de Prix

By TipRanks

12.74% hausse

Prévisions sur 12 Mois

Moyen 65.714 USD  12.74%

Haut 70 USD

Bas 62 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

7

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

11 / 339Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.